{
    "nct_id": "NCT05468489",
    "official_title": "A Randomized, Open-label Study of Serplulimab Plus Chemotherapy (Carboplatin-Etoposide) in Comparison With Atezolizumab Plus Chemotherapy in Previously Untreated US Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) (ASTRIDE)",
    "inclusion_criteria": "Voluntary participation in clinical studies.\n\nMale or female aged ≥ 18 years at the time of signing the ICF.\n\nHistologically or cytologically diagnosed with ES-SCLC (according to the Veterans Administration Lung Study Group staging system).\n\nNo prior systemic therapy for ES-SCLC.\n\nAt least one measurable lesion as assessed according to RECIST 1.1 within 4 weeks prior to randomization.\n\nMajor organs are functioning well.\n\nEvery effort should be made to provide tumor tissues for the determination of PD-L1 expression.\n\nAn ECOG PS score of 0 or 1.\n\nAn expected survival ≥ 12 weeks.\n\nSubjects with prior denosumab use that can and agree to switch to bisphosphonate therapy for bone metastases starting prior to randomization and throughout treatment.\n\nParticipant must keep contraception.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "Histologically or cytologically confirmed mixed SCLC.\n\nKnown history of severe allergy to any monoclonal antibody.\n\nKnown hypersensitivity to carboplatin or etoposide.\n\nPatients with myocardial infarction within half a year before the first dose of the study drug, poorly controlled arrhythmia.\n\nPregnant or breastfeeding females.\n\nPatients with a known history of psychotropic drug abuse or drug addiction.\n\nPatients who have other factors that could lead to the early termination of this study based on the investigator's judgment.",
    "miscellaneous_criteria": ""
}